NATERA Reports 31.9% Increase in Q2 FY2023 Revenue to USD 261.4 Million

August 14, 2023

☀️Earnings Overview

On June 30, 2023, NATERA ($NASDAQ:NTRA) released its second-quarter financial results for FY2023, with total revenue of USD 261.4 million, a rise of 31.9% compared to the same quarter of the prior year. Net income for the quarter was USD -110.8 million, a decrease from -145.2 million in the same quarter of the prior year.

Analysis

GoodWhale has conducted an analysis of NATERA‘s financials and has found that it is a high risk investment in terms of both financial and business aspects. Specifically, GoodWhale has detected risk warnings in the balance sheet, cashflow statement, non-financial, and financial journals. These risks include potential changes in customer base, large operating costs, limited financial resources, and the possibility of a weak revenue growth. The combination of these risks highlights the need for investors to be aware of potential risks associated with investing in NATERA. GoodWhale encourages investors to register on its website for more detailed analysis of NATERA’s financials and risk ratings. This will aid investors in making informed decisions about their investments in NATERA. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • NATERA_Reports_31.9_Increase_in_Q2_FY2023_Revenue_to_USD_261.4_Million”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Natera. NATERA_Reports_31.9_Increase_in_Q2_FY2023_Revenue_to_USD_261.4_Million”>More…

    Total Revenues Net Income Net Margin
    931.05 -511.79 -55.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Natera. NATERA_Reports_31.9_Increase_in_Q2_FY2023_Revenue_to_USD_261.4_Million”>More…

    Operations Investing Financing
    -342.65 151.2 481.18
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Natera. NATERA_Reports_31.9_Increase_in_Q2_FY2023_Revenue_to_USD_261.4_Million”>More…

    Total Assets Total Liabilities Book Value Per Share
    1.25k 651.75 5.23
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Natera are shown below. NATERA_Reports_31.9_Increase_in_Q2_FY2023_Revenue_to_USD_261.4_Million”>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    39.7% -53.7%
    FCF Margin ROE ROA
    -41.6% -50.1% -25.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items




  • Peers

    The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.

    – Genetic Technologies Ltd ($ASX:GTG)

    Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.

    – Dr Lalchandani Labs Ltd ($BSE:541299)

    Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.

    – NeoGenomics Inc ($NASDAQ:NEO)

    NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.

    Summary

    NATERA‘s Q2 FY2023 financial results displayed a revenue growth of 31.9% compared to the previous year’s quarter. Despite this, the company posted a net loss of USD -110.8 million, a decrease from the previous quarter’s -145.2 million. Investors should consider reviewing the company‚Äôs performance metrics and overall financial health before deciding whether to invest in NATERA shares. Furthermore, it is important to consider the macro-economic environment and any external factors that could affect the company’s performance in the future.

    Recent Posts

    Leave a Comment